JP2011507956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507956A5 JP2011507956A5 JP2010540673A JP2010540673A JP2011507956A5 JP 2011507956 A5 JP2011507956 A5 JP 2011507956A5 JP 2010540673 A JP2010540673 A JP 2010540673A JP 2010540673 A JP2010540673 A JP 2010540673A JP 2011507956 A5 JP2011507956 A5 JP 2011507956A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- concentration
- oral solid
- component
- solid formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013270 controlled release Methods 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 27
- 239000007787 solid Substances 0.000 claims 25
- 238000009472 formulation Methods 0.000 claims 23
- 150000001735 carboxylic acids Chemical class 0.000 claims 17
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 14
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 14
- 229960004502 levodopa Drugs 0.000 claims 14
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 6
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 4
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 229960004205 carbidopa Drugs 0.000 claims 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 208000014398 Parkinson disease 21 Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 235000010338 boric acid Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960001484 edetic acid Drugs 0.000 claims 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000004334 sorbic acid Substances 0.000 claims 1
- 235000010199 sorbic acid Nutrition 0.000 claims 1
- 229940075582 sorbic acid Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US945707P | 2007-12-28 | 2007-12-28 | |
| US61/009,457 | 2007-12-28 | ||
| PCT/US2008/014080 WO2009085306A1 (en) | 2007-12-28 | 2008-12-26 | Controlled release formulations of levodopa and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015145033A Division JP6033373B2 (ja) | 2007-12-28 | 2015-07-22 | レボドパの放出制御製剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011507956A JP2011507956A (ja) | 2011-03-10 |
| JP2011507956A5 true JP2011507956A5 (https=) | 2012-02-16 |
| JP5783725B2 JP5783725B2 (ja) | 2015-09-24 |
Family
ID=40824610
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540673A Active JP5783725B2 (ja) | 2007-12-28 | 2008-12-26 | レボドパの放出制御製剤及びその使用 |
| JP2015145033A Active JP6033373B2 (ja) | 2007-12-28 | 2015-07-22 | レボドパの放出制御製剤及びその使用 |
| JP2016208444A Active JP6328205B2 (ja) | 2007-12-28 | 2016-10-25 | レボドパの放出制御製剤及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015145033A Active JP6033373B2 (ja) | 2007-12-28 | 2015-07-22 | レボドパの放出制御製剤及びその使用 |
| JP2016208444A Active JP6328205B2 (ja) | 2007-12-28 | 2016-10-25 | レボドパの放出制御製剤及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US8377474B2 (https=) |
| EP (1) | EP2234963B1 (https=) |
| JP (3) | JP5783725B2 (https=) |
| KR (3) | KR101451564B1 (https=) |
| CN (1) | CN101910113A (https=) |
| AU (1) | AU2008343787B2 (https=) |
| CA (1) | CA2711014C (https=) |
| IL (3) | IL206756A (https=) |
| MX (1) | MX2010007207A (https=) |
| NZ (2) | NZ602302A (https=) |
| WO (1) | WO2009085306A1 (https=) |
| ZA (1) | ZA201005309B (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101910113A (zh) | 2007-12-28 | 2010-12-08 | 怡百克制药公司 | 左旋多巴控释制剂及其用途 |
| US20110166370A1 (en) | 2010-01-12 | 2011-07-07 | Charles Winston Saunders | Scattered Branched-Chain Fatty Acids And Biological Production Thereof |
| EP2629615B1 (en) | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| WO2013035053A2 (en) * | 2011-09-09 | 2013-03-14 | Kareus Therapeutics, Sa | Novel conjugation-facilitated transport of drugs across blood brain barrier |
| WO2014006571A2 (en) * | 2012-07-02 | 2014-01-09 | Ranbaxy Laboratories Limited | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof |
| SG11201503128TA (en) * | 2012-10-22 | 2015-05-28 | Civitas Therapeutics Inc | Reducing inter-patient variability of levodopa plasma concentrations |
| US20140150787A1 (en) * | 2012-12-04 | 2014-06-05 | Civitas Therapeutics, Inc. | Devices and methods for puncturing a capsule to release a powdered medicament therefrom |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| US10510914B2 (en) | 2013-03-21 | 2019-12-17 | Board Of Trustees Of Michigan State University | Transparent energy-harvesting devices |
| CN103417494B (zh) * | 2013-08-13 | 2015-12-23 | 杭州高成生物营养技术有限公司 | 一种以酒石酸作为主要成分的微丸 |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| CN105658211A (zh) | 2013-10-07 | 2016-06-08 | 怡百克制药公司 | 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途 |
| ES2882255T3 (es) | 2015-07-01 | 2021-12-01 | California Inst Of Techn | Sistemas de administración basados en polímeros de ácido múcico catiónicos |
| EP3184101A1 (en) | 2015-12-21 | 2017-06-28 | Sandoz Ag | Levodopa and carbidopa modified release composition |
| AU2017297718B2 (en) | 2016-07-11 | 2023-06-08 | Contera Pharma A/S | Pulsatile drug delivery system for treating morning akinesia |
| US10736905B1 (en) | 2016-09-09 | 2020-08-11 | Shahin Fatholahi | Nefopam dosage forms and methods of treatment |
| JP7066351B2 (ja) * | 2017-08-18 | 2022-05-13 | 大原薬品工業株式会社 | 良好な徐放性を有する、レボドパ含有小型化錠剤 |
| US11446311B2 (en) | 2017-09-08 | 2022-09-20 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| US10736874B1 (en) | 2017-09-08 | 2020-08-11 | Shahin Fatholahi | Methods for treating pain associated with sickle cell disease |
| WO2019165993A1 (zh) | 2018-02-28 | 2019-09-06 | 上海汉都医药科技有限公司 | 一种药物组合物及其制备方法和应用 |
| US12247126B2 (en) | 2018-05-09 | 2025-03-11 | Board Of Trustees Of Michigan State University | Near-infrared harvesting transparent luminescent solar concentrators with engineered stokes shift |
| US11911513B2 (en) | 2018-05-23 | 2024-02-27 | Shanghai Wd Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
| JP7125791B2 (ja) | 2018-05-23 | 2022-08-25 | シャンハイ ダブリュディー ファーマシューティカル カンパニー，リミティド | 活性薬物成分の放出制御システムおよびその製造方法 |
| WO2019241327A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| US11517548B2 (en) | 2018-07-19 | 2022-12-06 | Impel Pharmaceuticals Inc. | Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease |
| EP3857276A4 (en) | 2018-09-24 | 2022-08-03 | Board Of Trustees Of Michigan State University | TRANSPARENT LUMINESCENT SOLAR CONCENTRATOR |
| US11698461B1 (en) | 2019-11-20 | 2023-07-11 | Telephonics Corp. | GPS denial detection and reporting and mitigation |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| KR20230124622A (ko) | 2020-12-22 | 2023-08-25 | 암닐 파마슈티컬스 엘엘씨 | 레보도파 투여 요법 |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| CN114762684B (zh) * | 2021-01-14 | 2023-11-21 | 华益泰康药业股份有限公司 | 一种治疗帕金森的缓释胶囊及其制备方法 |
| CN113616621B (zh) * | 2021-08-19 | 2025-03-14 | 北京世桥生物制药有限公司 | 一种左旋多巴和卡比多巴控释制剂及其制备方法 |
| WO2025032501A1 (en) * | 2023-08-08 | 2025-02-13 | Alembic Pharmaceuticals Limited | Pharmaceutical composition comprising combination of levodopa and carbidopa |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3891696A (en) | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
| FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3126703A1 (de) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| DE252290T1 (de) | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| ZA889189B (en) | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| NZ220599A (en) | 1986-06-16 | 1990-10-26 | Merck & Co Inc | Controlled release oral dosage formulation of carbidopa and levodopa |
| EP0313845A1 (en) | 1987-09-29 | 1989-05-03 | Warner-Lambert Company | Stabilization of enteric coated dosage form |
| US4938968A (en) | 1988-07-26 | 1990-07-03 | Norjec Development Associates, Inc. | Controlled release indomethacin |
| IT1229856B (it) | 1989-04-20 | 1991-09-13 | Recordati Chem Pharm | Compresse a rilascio controllato contenenti flavossato. |
| IE66933B1 (en) | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
| DE4101873C2 (de) | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
| US5624960A (en) | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| JPH09500645A (ja) | 1993-07-22 | 1997-01-21 | ワーナー−ランバート・コンパニー | 制御放出タクリン薬物送達システムおよびその製造方法 |
| SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| US5840756A (en) | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| IT1282576B1 (it) | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| US6756056B2 (en) | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| IT1293764B1 (it) | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| WO2000015197A1 (en) | 1998-09-14 | 2000-03-23 | Rubin Alan A | Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| MXPA01004381A (es) | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Composicion de multiparticulado de liberacion modificada. |
| PT1140012E (pt) | 1998-12-17 | 2004-05-31 | Alza Corp | Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| IL159813A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
| IL159812A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
| US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US20040166159A1 (en) | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| NZ542303A (en) * | 2003-03-14 | 2008-12-24 | Nirmal Mulye | A process for preparing sustained release tablets |
| DE602004031134D1 (de) | 2003-08-29 | 2011-03-03 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| US8815950B2 (en) * | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| JP4188263B2 (ja) | 2004-03-01 | 2008-11-26 | ミツヤゴルフ株式会社 | 多用途利用可能なレール構造 |
| US8007827B2 (en) | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
| JP2008516893A (ja) | 2004-08-27 | 2008-05-22 | スフェリックス，インク． | 多層錠剤および生体接着性剤形 |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| MX2007011976A (es) * | 2005-03-28 | 2007-12-07 | Orexo Ab | Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson. |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| CA2613631A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| WO2007002518A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
| AR055106A1 (es) | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa |
| EP1919460A2 (en) | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| WO2007072911A1 (ja) | 2005-12-22 | 2007-06-28 | Asubio Pharma Co., Ltd. | 塩酸サプロプテリンの生体内吸収性を向上させた製剤 |
| CN101410094B (zh) * | 2006-01-27 | 2013-04-17 | 阿普塔利斯制药股份有限公司 | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 |
| KR20140088230A (ko) | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
| US8637080B2 (en) | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
| CN101910113A (zh) | 2007-12-28 | 2010-12-08 | 怡百克制药公司 | 左旋多巴控释制剂及其用途 |
| WO2011056240A2 (en) | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US20130195973A1 (en) | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| CN105658211A (zh) | 2013-10-07 | 2016-06-08 | 怡百克制药公司 | 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途 |
-
2008
- 2008-12-26 CN CN2008801227551A patent/CN101910113A/zh active Pending
- 2008-12-26 CA CA2711014A patent/CA2711014C/en active Active
- 2008-12-26 AU AU2008343787A patent/AU2008343787B2/en active Active
- 2008-12-26 KR KR1020107016189A patent/KR101451564B1/ko active Active
- 2008-12-26 KR KR1020157032127A patent/KR101752080B1/ko active Active
- 2008-12-26 KR KR1020137024633A patent/KR101569604B1/ko active Active
- 2008-12-26 WO PCT/US2008/014080 patent/WO2009085306A1/en not_active Ceased
- 2008-12-26 US US12/599,668 patent/US8377474B2/en active Active
- 2008-12-26 MX MX2010007207A patent/MX2010007207A/es active IP Right Grant
- 2008-12-26 NZ NZ602302A patent/NZ602302A/en unknown
- 2008-12-26 NZ NZ586870A patent/NZ586870A/xx unknown
- 2008-12-26 JP JP2010540673A patent/JP5783725B2/ja active Active
- 2008-12-26 EP EP08866933.8A patent/EP2234963B1/en not_active Revoked
-
2010
- 2010-07-01 IL IL206756A patent/IL206756A/en active IP Right Grant
- 2010-07-26 ZA ZA2010/05309A patent/ZA201005309B/en unknown
-
2012
- 2012-02-06 US US13/367,230 patent/US8454998B2/en active Active
- 2012-12-11 US US13/711,248 patent/US8557283B2/en active Active
-
2013
- 2013-05-22 US US13/900,408 patent/US9089607B2/en active Active
- 2013-09-18 US US14/030,813 patent/US9463246B2/en active Active
- 2013-09-18 US US14/030,792 patent/US9089608B2/en active Active
-
2015
- 2015-07-22 JP JP2015145033A patent/JP6033373B2/ja active Active
- 2015-12-04 US US14/958,975 patent/US9533046B2/en active Active
-
2016
- 2016-10-25 JP JP2016208444A patent/JP6328205B2/ja active Active
- 2016-10-26 IL IL248520A patent/IL248520B/en active IP Right Grant
- 2016-12-19 US US15/382,851 patent/US9901640B2/en active Active
-
2018
- 2018-11-15 IL IL263053A patent/IL263053A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507956A5 (https=) | ||
| JP7398999B2 (ja) | 薬物動態が改善された放出調節ガンマ－ヒドロキシ酪酸塩製剤 | |
| JP2019048843A5 (https=) | ||
| JP2011502997A5 (https=) | ||
| US20140045900A1 (en) | Administration regime for nitrocatechols | |
| JP2015526458A5 (https=) | ||
| KR20100099731A (ko) | 레보도파 방출 제어형 제제 및 이의 용도 | |
| JP2015504871A5 (https=) | ||
| JP2015512406A5 (https=) | ||
| KR20110046554A (ko) | 엔타카폰 또는 이의 염의 서방형 약학 조성물 | |
| JP2019116494A (ja) | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 | |
| JP2021525729A5 (https=) | ||
| WO2004032845A3 (en) | R-nsaid esters and their use | |
| JP2012502103A5 (https=) | ||
| JP2022502492A5 (https=) | ||
| JP2019529570A5 (https=) | ||
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2008519811A (ja) | 下肢静止不能症候群の治療 | |
| JP6704252B2 (ja) | 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬 | |
| JP2007520488A5 (https=) | ||
| JP2014513130A5 (https=) | ||
| MA et al. | Clonidine, moxonidine, folic acid, and mecobalamin improve baroreflex function in stroke‐prone, spontaneously hypertensive rats | |
| JP2014531470A5 (https=) | ||
| JP2018529747A5 (https=) | ||
| KR101078133B1 (ko) | 동방 결절 ｉｆ 흐름 억제제와 베타 차단제의 회합체 |